Clinical trials: LBCL
B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL)
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who…
- Conditions
- B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
- Trial name
- SOUNDTRACK-B (NCT06526793)
- Testing
- Surovatamig
- Where
- 94 sites in United States, Australia and 14 more
- Volunteers
- 270 people
- Sponsor
- AstraZeneca
Non-Hodgkin Lymphoma, Large B-cell Lymphoma
CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
This is an open-label, single-arm study to treat the adult R/R Large B-cell Lymphoma subjects with Relmacabtagene autoleucel (relma-cel) in China.
- Trial name
- NCT06479356
- Testing
- Relma-cel
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
Large B-cell Lymphoma
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
The purpose of this study is to measure the efficacy and safety of R-mini-CHOP × 2 followed by AZD0486 compared with R-mini-CHOP × 6 in elderly or unfit participants newly diagnosed with LBCL.
- Trial name
- SOUNDTRACK-D2 (NCT07215585)
- Testing
- AZD0486, R-mini-CHOP
- Where
- 82 sites in Australia, Belgium and 10 more
- Volunteers
- 420 people
- Sponsor
- AstraZeneca
DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
The goal of this clinical trial is to evaluate clinical efficacy of incorporating Epcoritamab into the salvage treatment routine for relapsed-refractory aggressive B-cell lymphoma, followed by autologous stem-cell transplantation…
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, DLBCL, Nos Genetic Subtypes
- Trial name
- NCT06287398
- Testing
- Epcoritamab
- Where
- Australia
- Volunteers
- 39 people
- Sponsor
- Australasian Leukaemia and Lymphoma Group
Large-cell Lymphoma
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
This is a phase 1b clinical trial to assess the efficacy of rapcabtagene autoleucel (YTB323) administered at the recommended dose in adults with Large B Cell Lymphoma (LBCL) who are at high risk of relapse at end of first line…
- Trial name
- NCT07443137
- Testing
- Rapcabtagene autoleucel (YTB323)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
This is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as…
- Trial name
- NCT06104592
- Testing
- Comprehensive Ablative Bridging Irradiation (CABI), Chimeric Antigen Receptor T-Cell Therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma, Large B-cell Lymphoma (LBCL)
Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS
The purpose of this study is to evaluate emapalumab as a prophylactic therapy in preventing cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients with hematologic…
- Trial name
- NCT07567014
- Testing
- Emapalumab
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- NYU Langone Health
Large B-Cell Lymphoma (LBCL)
AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL
This is a prospective, open-label, multicenter, randomized controlled study in participants with previously untreated large B-cell lymphoma.
- Trial name
- GUIDANCE-10 (NCT07594899)
- Testing
- Polatuzumab Vedotin, rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Ruijin Hospital
High-risk R/R LBCL
CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.
This is a prospective, single-arm, single-center, open-label clinical study, aiming to evaluate the efficacy and safety of CAR-T combined with ASCT in the treatment of relapsed/refractory large B-cell lymphoma with high-risk…
- Trial name
- CAR-T+ASCT (NCT07538635)
- Testing
- Axicabtagene Ciloleucel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
This phase II trial tests how well epcoritamab in combination with standard of care (SOC) platinum-based chemotherapy (rituximab, ifosfamide, carboplatin, etoposide [RICE], rituximab, cytarabine, dexamethasone, oxaliplatin or…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements
- Trial name
- NCT06905509
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, Davis
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
This phase Ib trial studies the effects of NKTR-255 in combination with chimeric antigen (CAR)-T cell therapy and to see how well they work in treating patients with large B-cell lymphoma that has come back (relapsed) or does not…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma
- Trial name
- NCT05359211
- Testing
- Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Fred Hutchinson Cancer Center
B-cell Malignancies
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
- Trial name
- TITANium (NCT06542250)
- Testing
- AZD5492
- Where
- 31 sites in United States, Australia and 8 more
- Volunteers
- 174 people
- Sponsor
- AstraZeneca
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
This is a single-arm, open label, multicenter Phase 1/2 study evaluating ALLO-501A in adult subjects with R/R LBCL and CLL/SLL. The purpose of the ALPHA2 study is to assess the safety, efficacy, and cell kinetics of ALLO-501A in…
- Trial name
- ALPHA2 (NCT04416984)
- Testing
- ALLO-501A, ALLO-647, Fludarabine
- Where
- 29 sites in United States, Australia and 1 more
- Volunteers
- 160 people
- Sponsor
- Allogene Therapeutics
High-risk Large B-cell Lymphoma (LBCL)
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
- Trial name
- ZUMA-23 (NCT05605899)
- Testing
- Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
- Where
- 85 sites in United States, Australia and 10 more
- Volunteers
- 300 people
- Sponsor
- Kite, A Gilead Company
NHL, DLBCL - Diffuse Large B Cell Lymphoma
Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL
A phase II, multi-center study to compare the feasibility, and clinical efficacy of local manufacturing of CD19-directed CAR T-cells (ARI-0001 CAR T-cells) with commercial produced CAR T-cells (for example axicabtagene…
- Trial name
- HOVON161 (NCT05641428)
- Testing
- ARI-0001, Axi-cel
- Where
- 7 sites in Netherlands
- Volunteers
- 340 people
- Sponsor
- University Medical Center Groningen
CAR-T Retreatment
Axi-cel Retreatment in Relapsed/Refractory LBCL
This is a prospective, single-arm, clinical study to explore the efficacy and safety of Axi-cel retreatment in R/R LBCL in Shanghai Ruijin Hospital in China.
- Trial name
- NCT05800067
- Testing
- axi-cel
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Ruijin Hospital
CAR-T Cell Therapy, High-risk Large B-cell Lymphoma (LBCL)
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma
The goal of this is Single-Arm, Multicenter, Open-Label Clinical Study is to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection(Axi-cel) as First-Line Therapy of High-Risk Large B-Cell Lymphoma.
- Trial name
- NCT06935136
- Testing
- Axicabtagene Ciloleucel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Ruijin Hospital
Large B-cell Lymphoma, Lymphoma
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
To learn if loncastuximab tesirine (called "lonca" in this informed consent form) can help to control large B-cell lymphoma that is relapsed or refractory after receiving CAR T-cell therapy.
- Trial name
- NCT05464719
- Testing
- Loncastuximab Tesirine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed/Refractory Large B Cell Lymphoma, Relapsed/Refractory Follicular Lymphoma
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma
The purpose of the ALPHA study is to assess the safety, efficacy, cell kinetics and immunogenicity of ALLO-501 in adults with relapsed or refractory large B-cell lymphoma or follicular lymphoma after a lymphodepletion regimen…
- Trial name
- ALPHA (NCT03939026)
- Testing
- ALLO-501, ALLO-647, Fludarabine
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Allogene Therapeutics
DLBCL, Diffuse Large B Cell Lymphoma
Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL
This is a multicenter Phase I study to determine the maximum tolerated dose (MTD) of E7777 when given prior to cyclophosphamide/fludarabine (CY/Flu) lymphodepletion (LD) chemotherapy and an FDAapproved CAR-T product…
- Conditions
- DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, DLBCL Arising From Follicular Lymphoma
- Trial name
- NCT04855253
- Testing
- E7777, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Masonic Cancer Center, University of Minnesota